Protara Therapeutics, Inc.
TARA
$3.41
-$0.115-3.27%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.45M | 17.30M | 17.52M | 18.14M | 18.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.15M | 45.88M | 44.25M | 45.73M | 43.61M |
| Operating Income | -49.15M | -45.88M | -44.25M | -45.73M | -43.61M |
| Income Before Tax | -44.60M | -42.05M | -40.69M | -42.47M | -40.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.60 | -42.05 | -40.69 | -42.47 | -40.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.60M | -42.05M | -40.69M | -42.47M | -40.42M |
| EBIT | -49.15M | -45.88M | -44.25M | -45.73M | -43.61M |
| EBITDA | -48.82M | -45.53M | -43.90M | -45.39M | -43.27M |
| EPS Basic | -2.41 | -2.82 | -3.19 | -3.74 | -3.57 |
| Normalized Basic EPS | -1.50 | -1.76 | -1.99 | -2.34 | -2.23 |
| EPS Diluted | -2.41 | -2.82 | -3.19 | -3.74 | -3.57 |
| Normalized Diluted EPS | -1.50 | -1.76 | -1.99 | -2.34 | -2.23 |
| Average Basic Shares Outstanding | 81.42M | 66.35M | 55.37M | 45.44M | 45.32M |
| Average Diluted Shares Outstanding | 81.42M | 66.35M | 55.37M | 45.44M | 45.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |